fbpx COVID-19 (Coronavirus): ADB's Response | Asian Development Bank

COVID-19 (Coronavirus): ADB's Response

ADB is supporting its developing members in responding to the COVID-19 pandemic through finance, knowledge, and partnerships.

In the Spotlight

How to Recover Learning Losses from COVID-19 School Closures in Asia and the Pacific

Publication | 18 July 2022

How to Recover Learning Losses from COVID-19 School Closures in Asia and the Pacific

This brief provides insights on how learning losses caused by the closure of schools during the coronavirus disease (COVID-19) pandemic can be recovered in Asia and the Pacific.

Trade Interdependencies in COVID-19-Related Essential Medical Goods: Role of Trade Facilitation and Cooperation for the Asian Economies

Publication | 30 June 2022

Trade Interdependencies in COVID-19-Related Essential Medical Goods: Role of Trade Facilitation and Cooperation for the Asian Economies

This paper analyzes how regional trade agreements (RTAs) among Asian economies affected the supply of essential medical goods in the context of the COVID-19 pandemic.

ADB Approves $10 Million for COVID-19 Vaccines in Bhutan

News Release | 1 August 2022

ADB Approves $10 Million for COVID-19 Vaccines in Bhutan

ADB has approved a $10 million loan to help the Government of Bhutan purchase safe and effective vaccines against COVID-19.

ADB’s COVID-19 Response for Developing Asia Surpasses $20 Billion

Article | 13 September 2021

ADB’s COVID-19 Response for Developing Asia Surpasses $20 Billion

ADB’s committed assistance to help its developing member countries address the COVID-19 pandemic including vaccination support has surpassed $20 billion

ADB’s COVID-19 response consists of a $20 billion package announced in April 2020 and the $9 billion Asia Pacific Vaccine Access Facility (APVAX) announced in December 2020.

ADB’s initial $20 billion COVID-19 response package supports its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (non-sovereign).

ADB's $9 billion APVAX vaccine initiative offers rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*Projects may be listed in more than one country or subregion. The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.

News and Multimedia   Subscribe to our newsletter

Publications and Documents


Milestones

Made with Flourish